BioAtla is changing the future of medicine and personalized health. We employ our science and proprietary technologies to solve critical protein development challenges and produce novel, IP-protectable products both for our clients and our own product portfolio.

The culmination of our technological capabilities is our widely applicable platform technology known as Conditionally Active Biologics (CABs). CAB-designed monoclonal antibodies selectively bind their antigen when it is present in tumor tissue for example, leaving healthy cells unharmed. This approach enables improved safety and therapeutic index, and allows higher dosing and thus increased potency and sustained treatment. CAB technology also expands the universe of potential targets for oncology and other diseases by conferring greater specificity for diseased tissue.

Drawing on deep in house experience in protein and antibody engineering, and with labs in San Diego and Beijing, Bioatla works around the clock to efficiently and cost-effectively execute programs for our clients (pharma, biotechs, and academic researchers) as well as for our internal programs.